PDS Biotechnology
PDSB
51 hedge funds and large institutions have $19.2M invested in PDS Biotechnology in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 12 closing their positions.
170% more call options, than puts
Call options by funds: $2.64M | Put options by funds: $978K
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 52 → 51 (-1)
1.96% less ownership
Funds ownership: 20.58% → 18.62% (-2%)
47% less capital invested
Capital invested by funds: $36.2M → $19.2M (-$17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$925K |
| 2 |
Millennium Management
New York
|
+$715K |
| 3 |
VF
Virtu Financial
New York
|
+$225K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$207K |
| 5 |
IWA
Inspirion Wealth Advisors
Libertyville,
Illinois
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.75M |
| 2 |
Renaissance Technologies
New York
|
-$1.3M |
| 3 |
FAM
Fred Alger Management
New York
|
-$737K |
| 4 |
D.E. Shaw & Co
New York
|
-$514K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$446K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Bank of Montreal
Toronto,
Ontario, Canada
| $249 | +$207K | +43,500 | New |
|
|
ACM
52
AIGH Capital Management
Baltimore,
Maryland
| – | -$1.75M | -282,609 | Closed |
|
|
FAM
53
Fred Alger Management
New York
| – | -$737K | -119,082 | Closed |
|
|
54
D.E. Shaw & Co
New York
| – | -$514K | -83,112 | Closed |
|
|
WVP
55
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$436K | -70,378 | Closed |
|
56
Goldman Sachs
New York
| – | -$184K | -29,752 | Closed |
|
|
AA
57
ALPS Advisors
Denver,
Colorado
| – | -$181K | -29,221 | Closed |
|
|
GCP
58
GSA Capital Partners
London,
United Kingdom
| – | -$89K | -14,321 | Closed |
|
59
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$86K | -13,862 | Closed |
|
|
IC
60
Ikarian Capital
Dallas,
Texas
| – | -$22K | -3,672 | Closed |
|
61
UBS Group
Zurich,
Switzerland
| – | -$15K | -2,499 | Closed |
|
62
Rockefeller Capital Management
New York
| – | -$5K | -955 | Closed |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$1K | -124 | Closed |
|
PDSB Hedge Fund Activity: Q2 2022 in Review
51 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2022, worth a combined $19.2M — down 47% from $36.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PDSB and 11 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 13 added.
The largest buyer was LPL Financial, opening a new position worth an estimated $925K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.75M sold.
- 51 institutional investors held PDS Biotechnology (PDSB) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $19.2M of PDS Biotechnology stock for Q2 2022, down 47% quarter-over-quarter.
- 11 funds opened new PDS Biotechnology positions in Q2 2022 and 12 closed out, a net change of -1 holder.
- The largest PDS Biotechnology buyer in Q2 2022 was LPL Financial, an estimated $925K added.
- The largest PDS Biotechnology seller in Q2 2022 was AIGH Capital Management, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2022.